The five-year relative survival rate for stage 4 melanoma (melanoma that has spread to distant organs) is about 34.6%, based on data from the National Cancer Institute’s SEER program covering 2015 through 2021. That number represents a dramatic improvement from just a decade ago, when the same figure hovered around 5%. The shift is almost entirely due to immunotherapy and targeted therapy drugs that became available starting in 2011.
But a single statistic doesn’t capture what any individual person can expect. How long someone lives with stage 4 melanoma depends heavily on where the cancer has spread, the tumor’s genetic profile, how well it responds to treatment, and overall health at diagnosis.
What the Survival Numbers Actually Mean
A 34.6% five-year survival rate means that out of 100 people diagnosed with distant-stage melanoma, roughly 35 are alive five years later. This is a population average, not a prediction for any one person. It also reflects outcomes for people diagnosed several years ago, meaning it likely underestimates current survival since newer treatments continue to improve results.
Median survival, which is the point at which half of patients are still alive and half have died, varies widely by treatment type and disease characteristics. For patients with a specific genetic mutation called BRAF V600 who receive targeted therapy, the median overall survival is around 20 months, with about 69% alive at one year and 41.5% alive at two years. Patients treated with combination immunotherapy often do better, and a meaningful subset achieve long-term remission that lasts years or even indefinitely.
Where the Cancer Spreads Matters Enormously
Stage 4 melanoma can spread to the lungs, liver, bones, or brain, and the location of those metastases is one of the strongest predictors of how long someone survives. Brain metastases historically carried the worst prognosis. In one study of melanoma patients with brain involvement, median overall survival was about 10 months for the full group. Patients who received focused brain treatments like surgery or stereotactic radiosurgery had median survival times of 10 to 17 months, with some reaching three years. Patients who received only systemic treatment without any direct brain intervention had a median survival of just 1.2 months, and none in that group survived to three years.
Melanoma that has spread only to soft tissue or distant lymph nodes tends to carry a better prognosis than cancer in the liver or brain. Your oncologist will factor the number of metastatic sites and the specific organs involved into your outlook.
Blood Markers and What They Signal
One of the most reliable indicators of prognosis in stage 4 melanoma is a blood enzyme called LDH (lactate dehydrogenase). Higher levels signal more aggressive disease. In clinical data, the relationship is strikingly clear: patients with very low LDH levels had a median survival of around 12 months, while those with even mildly elevated levels (just above the normal range) dropped to about 9 months. The higher the LDH climbed, the shorter survival became. This gradient was statistically significant across multiple trials and is one reason LDH is part of the standard staging system for melanoma.
How Immunotherapy Changed the Outlook
Before 2011, stage 4 melanoma was considered nearly untreatable. Chemotherapy produced response rates below 15%, and almost no one achieved long-lasting remission. The introduction of checkpoint inhibitors, drugs that essentially release the brakes on the immune system so it can attack cancer cells, transformed the disease.
Combination immunotherapy using two checkpoint inhibitors together produces the highest response rates. Among patients who achieve a complete response (meaning no detectable cancer on scans), the durability is remarkable. A real-world study from the Netherlands found that over 70% of patients who achieved a complete response on first-line immunotherapy remained progression-free, and more than 90% survived beyond three years. For many of these patients, remission persisted even after stopping treatment entirely, raising the possibility of what researchers describe as a “functional cure.”
Not everyone responds this well. Roughly 40 to 50% of patients do not respond to immunotherapy at all, and some respond initially but later relapse. Still, the existence of a durable long-term survivor population is something that simply did not exist before these treatments.
Targeted Therapy for BRAF-Positive Tumors
About 40 to 50% of melanomas carry a mutation in the BRAF gene. These tumors can be treated with a combination of two targeted drugs that block the mutated growth pathway. Median overall survival on this targeted therapy is about 20 months, though the range is enormous: some patients in clinical data survived beyond eight years on these treatments.
For patients whose BRAF-positive melanoma progresses after immunotherapy, targeted therapy remains an effective second option. One-year survival on targeted therapy after prior immunotherapy is around 69%.
A newer approach combines all three drug types: two targeted drugs plus an immunotherapy agent. This triple combination improved progression-free survival by about 4.5 months compared to targeted therapy alone (15.1 versus 10.6 months) and pushed the two-year survival rate to roughly 64%, compared to 56% with the two-drug regimen. This combination received FDA approval for BRAF-mutated melanoma.
Age, Sex, and Individual Variation
Younger patients generally fare somewhat better with earlier-stage melanoma, but by stage 4, the advantage narrows considerably. Population data shows that five-year survival for stage 4 disease drops below 20% across age groups, with minimal observable difference between younger and older adults at the five-year mark. Among younger patients specifically, females have a slight edge, with about 25% surviving five years compared to 20% for males.
Overall fitness matters as well. Patients who are active and have fewer other health conditions tend to tolerate aggressive treatment better and live longer. The number and size of metastases at diagnosis, how quickly the cancer is growing, and whether it responds to the first line of treatment are all powerful predictors that outweigh age alone.
What These Numbers Mean for You
Stage 4 melanoma survival statistics are changing faster than almost any other cancer type. The five-year rate has roughly quintupled in the past decade, and treatments continue to advance. The numbers you find online often reflect outcomes from years ago and may understate what current patients can expect.
The most meaningful factors for any individual are the tumor’s genetic profile (especially BRAF status), where metastases are located, LDH levels, and how the cancer responds to initial treatment. A person whose melanoma achieves a complete response on immunotherapy has a genuinely different trajectory than someone whose cancer does not respond. For the subset who achieve deep, lasting responses, survival measured in years, not months, is increasingly realistic.